- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02493764
Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014) (RESTORE-IMI 2)
April 3, 2020 updated by: Merck Sharp & Dohme LLC
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Subjects With Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
This study aims to compare treatment with a fixed-dose combination (FDC) of imipenem/relebactam/cilastatin (IMI/REL) with a FDC of piperacillin/tazobactam (PIP/TAZ) in participants with hospital-acquired or ventilator-associated bacterial pneumonia (HABP or VAPB, respectively).
The primary hypothesis is that IMI/REL is non-inferior to PIP/TAZ in the incidence rate of all-cause mortality.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
537
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Requires treatment with IV antibiotic therapy for hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP)
- Fulfills clinical and radiographic criteria, with onset of criteria occurring after more than 48 hours of hospitalization or within 7 days after discharge from a hospital (for HABP); or at least 48 hours after mechanical ventilation (for VABP)
- Has an adequate baseline lower respiratory tract specimen obtained for Gram stain and culture
- Has an infection known or thought to be caused by microorganisms susceptible to the IV study therapy
- Agrees to allow any bacterial isolates obtained from protocol-required specimens related to the current infection to be provided to the Central Microbiology Reference Laboratory for study-related microbiological testing, long term storage, and other future testing
- Is not of reproductive potential; or if of reproductive potential agrees to avoid impregnating a partner or avoid becoming pregnant, by practicing abstinence or using acceptable contraception
Exclusion Criteria:
- Has a baseline lower respiratory tract specimen Gram stain that shows the presence of Gram-positive cocci only
- Has confirmed or suspected community-acquired bacterial pneumonia (CABP)
- Has confirmed or suspected pneumonia of viral, fungal or parasitic origin
- Has HABP/VABP caused by an obstructive process, including lung cancer or other known obstruction
- Has a carcinoid tumor or carcinoid syndrome
- Has active immunosuppression defined as either receiving immunosuppressive medications or having a medical condition associated with immunodeficiency
- Is expected to survive for less than 72 hours
- Has a concurrent condition or infection that would preclude evaluation of therapeutic response
- Has received effective antibacterial drug therapy for the index infection of HABP/VABP for more than 24 hours continuously, during the previous 72 hours
- Has a history of serious allergy, hypersensitivity or a serious reaction to any penicillin or beta-lactamase inhibitors
- Female is pregnant, expecting to conceive, is breastfeeding or plans to breastfeed
- Has a history of seizure disorder requiring ongoing prior treatment with anti-convulsive therapy within the last 3 years
- Anticipates treatment with the following: valproic acid or divalproex sodium, serotonin re-uptake inhibitors, tricyclic antidepressants, or serotonin receptor antagonists, meperidine, buspirone, concomitant systemic antibacterial agents, antifungal or antiviral therapy for the index infection of HABP/VABP
- Is currently undergoing hemodialysis or peritoneal dialysis
- Is currently participating in, has participated in during the previous 30 days, or anticipates to participate in any other clinical study involving the administration of experimental medication
- Has previously participated in this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: IMI/REL
Imipenem 500 mg + relebactam 250 mg + cilastatin 500 mg as a FDC administered intravenously (IV) every 6 hours for a minimum of 7 days, up to 14 days.
At study entry open label linezolid 600 mg will also be administered by IV every 12 hours for up to 14 days.
|
Imipenem 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
Relebactam 250 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
Cilastatin 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
Linezolid 600 mg administered open-label by IV every 12 hours for up to 14 days
|
ACTIVE_COMPARATOR: PIP/TAZ
Piperacillin 4000 mg + tazobactam 500 mg as a FDC administered IV every 6 hours for a minimum of 7 days, up to 14 days.
At study entry open label linezolid 600 mg will also be administered by IV every 12 hours for up to 14 days.
|
Linezolid 600 mg administered open-label by IV every 12 hours for up to 14 days
Piperacillin 4000 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
Tazobactam 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With All-cause Mortality (ACM) Through Day 28 in the Modified Intention-to-treat (MITT) Population
Time Frame: Up to 28 days
|
The percentage of participants in the MITT population with mortality due to any cause from randomization through Day 28 was determined for each arm.
|
Up to 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants in the MITT Population With a Favorable Clinical Response (FCR) at Early Follow-up (EFU) Visit
Time Frame: Up to 16 days after end of therapy (up to 30 days)
|
The percentage of participants with a FCR at EFU was determined for each arm.
Favorable clinical response at EFU was defined as either "sustained cure" (all pre-therapy signs and symptoms of the index infection have resolved [or returned to "pre-infection status"] with no evidence of resurgence and no additional antibiotics are required) or "cure" (all pre-therapy signs and symptoms of the index infection have resolved [or returned to "pre-infection status"] and no additional antibiotics are required).
|
Up to 16 days after end of therapy (up to 30 days)
|
Percentage of Participants With ≥1 Adverse Event (AE)
Time Frame: Up to 30 days
|
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
|
Up to 30 days
|
Percentage of Participants Discontinuing Study Therapy Due to an AE
Time Frame: Up to 14 days
|
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
|
Up to 14 days
|
Percentage of Participants With ACM in the Microbiological Modified Intention-to-treat (mMITT) Population
Time Frame: Up to 28 days
|
The percentage of participants in the mMITT population with mortality due to any cause from randomization through Day 28 was determined for each arm.
|
Up to 28 days
|
Percentage of Participants With ACM at EFU in the MITT Population
Time Frame: Up to 16 days after end of therapy (up to 30 days)
|
The percentage of participants in the MITT population with mortality due to any cause from randomization through EFU was determined for each arm.
|
Up to 16 days after end of therapy (up to 30 days)
|
Percentage of Participants With ACM at EFU in the mMITT Population
Time Frame: Up to 16 days after end of therapy (up to 30 days)
|
The percentage of participants in the mMITT population with mortality due to any cause from randomization through EFU was determined for each arm.
|
Up to 16 days after end of therapy (up to 30 days)
|
Percentage of Participants in the Clinically Evaluable (CE) Population With a FCR at On-therapy Visit 1 (OTX1) [Day 3]
Time Frame: Day 3 (OTX1)
|
The percentage of participants with a FCR at OTX1 was determined for each arm.
Favorable clinical response at OTX1 was defined as "improved" (majority of pre-therapy signs and symptoms of the index infection have improved or resolved [or returned to "pre-infection status"]).
|
Day 3 (OTX1)
|
Percentage of Participants in the CE Population With a FCR at OTX2 (Day 6)
Time Frame: Day 6 (OTX2)
|
The percentage of participants with a FCR at OTX2 was determined for each arm.
Favorable clinical response at OTX2 was defined as "improved" (majority of pre-therapy signs and symptoms of the index infection have improved or resolved [or returned to "pre-infection status"]).
|
Day 6 (OTX2)
|
Percentage of Participants in the CE Population With a FCR at OTX3 (Day 10)
Time Frame: Day 10 (OTX3)
|
The percentage of participants with a FCR at OTX3 was determined for each arm.
Favorable clinical response at OTX3 was defined as "improved" (majority of pre-therapy signs and symptoms of the index infection have improved or resolved [or returned to "pre-infection status"]).
|
Day 10 (OTX3)
|
Percentage of Participants in the CE Population With a FCR at EOT Visit
Time Frame: From Day 7 to Day 14
|
The percentage of participants with a FCR at EOT was determined for each arm.
Favorable clinical response at EOT was defined as either "cure" (all pre-therapy signs and symptoms of the index infection have resolved [or returned to "pre-infection status"] and no additional antibiotics are required) or "improved" (the majority of pre-therapy signs and symptoms of the index infection have improved or resolved [or returned to "pre-infection status"] and no additional antibiotics are required).
|
From Day 7 to Day 14
|
Percentage of Participants in the CE Population With a FCR at Day 28
Time Frame: Day 28
|
The percentage of participants with a FCR at Day 28 was determined for each arm.
Favorable clinical response at Day 28 was defined as either "sustained cure" (all pre-therapy signs and symptoms of the index infection have resolved [or returned to "pre-infection status"] with no evidence of resurgence and no additional antibiotics are required) or "cure" (all pre-therapy signs and symptoms of the index infection have resolved [or returned to "pre-infection status"] and no additional antibiotics are required).
|
Day 28
|
Percentage of Participants in the CE Population With a FCR at EFU Visit
Time Frame: Up to 16 days after end of therapy (up to Day 30)
|
The percentage of participants with a FCR at EFU was determined for each arm.
Favorable clinical response at EFU was defined as either "sustained cure" (all pre-therapy signs and symptoms of the index infection have resolved [or returned to "pre-infection status"] with no evidence of resurgence and no additional antibiotics are required) or "cure" (all pre-therapy signs and symptoms of the index infection have resolved [or returned to "pre-infection status"] and no additional antibiotics are required).
|
Up to 16 days after end of therapy (up to Day 30)
|
Percentage of Participants in the MITT Population With a FCR at OTX1 (Day 3)
Time Frame: Day 3 (OTX1)
|
The percentage of participants with a FCR at OTX1 was determined for each arm.
Favorable clinical response at OTX1 was defined as "improved" (majority of pre-therapy signs and symptoms of the index infection have improved or resolved [or returned to "pre-infection status"]).
|
Day 3 (OTX1)
|
Percentage of Participants in the MITT Population With a FCR at OTX2 (Day 6)
Time Frame: Day 6 (OTX2)
|
The percentage of participants with a FCR at OTX2 was determined for each arm.
Favorable clinical response at OTX2 was defined as "improved" (majority of pre-therapy signs and symptoms of the index infection have improved or resolved [or returned to "pre-infection status"]).
|
Day 6 (OTX2)
|
Percentage of Participants in the MITT Population With a FCR at OTX3 (Day 10)
Time Frame: Day 10 (OTX3)
|
The percentage of participants with a FCR at OTX3 was determined for each arm.
Favorable clinical response at OTX3 was defined as "improved" (majority of pre-therapy signs and symptoms of the index infection have improved or resolved [or returned to "pre-infection status"]).
|
Day 10 (OTX3)
|
Percentage of Participants in the MITT Population With a FCR at EOT
Time Frame: From Day 7 to Day 14
|
The percentage of participants with a FCR at EOT was determined for each arm.
Favorable clinical response at EOT was defined as either "cure" (all pre-therapy signs and symptoms of the index infection have resolved [or returned to "pre-infection status"] and no additional antibiotics are required) or "improved" (the majority of pre-therapy signs and symptoms of the index infection have improved or resolved [or returned to "pre-infection status"] and no additional antibiotics are required).
|
From Day 7 to Day 14
|
Percentage of Participants in the MITT Population With a FCR at Day 28
Time Frame: Day 28
|
The percentage of participants with a FCR at Day 28 was determined for each arm.
Favorable clinical response at Day 28 was defined as either "sustained cure" (all pre-therapy signs and symptoms of the index infection have resolved [or returned to "pre-infection status"] with no evidence of resurgence and no additional antibiotics are required) or "cure" (all pre-therapy signs and symptoms of the index infection have resolved [or returned to "pre-infection status"] and no additional antibiotics are required).
|
Day 28
|
Percentage of Participants in the mMITT Population With a Favorable Microbiological Response (FMR) at End of Treatment (EOT) Visit
Time Frame: From Day 7 to Day 14
|
The percentage of participants with a FMR at EOT was determined for each arm.
Favorable microbiological response at EOT was defined as either "eradication" (a lower respiratory tract culture taken at EOT showing eradication of baseline pathogen) or "presumed eradication" (no specimen collected because the participant deemed clinically cured or improved).
|
From Day 7 to Day 14
|
Percentage of Participants in the mMITT Population With a FMR at EFU Visit
Time Frame: Up to 16 days after end of therapy (up to Day 30)
|
The percentage of participants with a FMR at EFU was determined for each arm.
Favorable microbiological response at EOT was defined as either "eradication" (a lower respiratory tract culture taken at EFU showing eradication of baseline pathogen) or "presumed eradication" (no specimen collected because the participant deemed clinically cured or improved).
|
Up to 16 days after end of therapy (up to Day 30)
|
Percentage of Participants in the Microbiologically Evaluable (ME) Population With a FMR at EOT Visit
Time Frame: From Day 7 to Day 14
|
The percentage of participants with a FMR at EOT was determined for each arm.
Favorable microbiological response at EOT was defined as either "eradication" (a lower respiratory tract culture taken at EOT showing eradication of baseline pathogen) or "presumed eradication" (no specimen collected because the participant deemed clinically cured or improved).
|
From Day 7 to Day 14
|
Percentage of Participants in the ME Population With a FMR at EFU Visit
Time Frame: Up to 16 days after end of therapy (up to Day 30)
|
The percentage of participants with a FMR at EOT was determined for each arm.
Favorable microbiological response at EOT was defined as either "eradication" (a lower respiratory tract culture taken at EOT showing eradication of baseline pathogen) or "presumed eradication" (no specimen collected because the participant deemed clinically cured or improved).
|
Up to 16 days after end of therapy (up to Day 30)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Patel M, Bellanti F, Daryani NM, Noormohamed N, Hilbert DW, Young K, Kulkarni P, Copalu W, Gheyas F, Rizk ML. Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital-acquired/ventilator-associated bacterial pneumonia. Clin Transl Sci. 2022 Feb;15(2):396-408. doi: 10.1111/cts.13158. Epub 2021 Oct 27.
- Titov I, Wunderink RG, Roquilly A, Rodriguez Gonzalez D, David-Wang A, Boucher HW, Kaye KS, Losada MC, Du J, Tipping R, Rizk ML, Patel M, Brown ML, Young K, Kartsonis NA, Butterton JR, Paschke A, Chen LF. A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study). Clin Infect Dis. 2021 Dec 6;73(11):e4539-e4548. doi: 10.1093/cid/ciaa803.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
November 24, 2015
Primary Completion (ACTUAL)
April 3, 2019
Study Completion (ACTUAL)
April 3, 2019
Study Registration Dates
First Submitted
July 7, 2015
First Submitted That Met QC Criteria
July 7, 2015
First Posted (ESTIMATE)
July 9, 2015
Study Record Updates
Last Update Posted (ACTUAL)
April 16, 2020
Last Update Submitted That Met QC Criteria
April 3, 2020
Last Verified
March 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lung Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Pneumonia
- Pneumonia, Bacterial
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Protease Inhibitors
- Anti-Bacterial Agents
- Protein Synthesis Inhibitors
- beta-Lactamase Inhibitors
- Linezolid
- Imipenem
- Relebactam
- Cilastatin
- Piperacillin
- Tazobactam
Other Study ID Numbers
- 7655A-014
- 2015-000246-34 (EUDRACT_NUMBER)
- 163240 (REGISTRY: JAPIC-CTI)
- MK-7655A-014 (OTHER: Merck Protocol Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bacterial Pneumonia
-
Evopoint Biosciences Inc.RecruitingHospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial PneumoniaUnited States, Spain, France, Israel
-
Merck Sharp & Dohme LLCCompletedHospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial PneumoniaMexico, Brazil, China, France, Philippines, Romania, Russian Federation, Ukraine
-
Omnix Medical LtdNot yet recruitingVentilator-associated Bacterial Pneumonia | Hospital-acquired Bacterial Pneumonia
-
Massachusetts General HospitalUnited States Agency for International Development (USAID)UnknownInfections - Bacterial | Pneumonia - BacterialPakistan
-
Melinta Therapeutics, Inc.WithdrawnHospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial Pneumonia | Hospital-Acquired Pneumonia | Ventilator-Associated Pneumonia
-
Zai Lab (Hong Kong), Ltd.RecruitingCommunity-acquired Bacterial PneumoniaUnited States
-
Melinta Therapeutics, Inc.Biomedical Advanced Research and Development AuthorityTerminatedCommunity-acquired Bacterial PneumoniaSpain, United States, Philippines, Hungary, United Kingdom, Bulgaria
-
Melinta Therapeutics, Inc.CompletedCommunity-Acquired Bacterial PneumoniaUnited States, Canada
-
Fundación Pública Andaluza para la gestión de la...European CommissionCompletedVentilator-associated Bacterial PneumoniaSpain, Italy, Greece
-
Albany Medical CollegeForest Laboratories; Albany College of Pharmacy and Health SciencesCompletedCommunity Acquired Bacterial PneumoniaUnited States
Clinical Trials on Imipenem
-
Tunis UniversityCompletedPneumonia, Ventilator-AssociatedTunisia
-
Sutep JaruratanasirikulPrince of Songkla UniversityCompletedVentilator-Associated PneumoniaThailand
-
Assistance Publique - Hôpitaux de ParisCompletedVentilator Associated PneumoniaFrance
-
Central Hospital, Nancy, FranceTerminated
-
Institute of Liver and Biliary Sciences, IndiaCompletedSpontaneous Bacterial PeritonitisIndia
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and Development; Fo...CompletedFebrile Neutropenia | Hematological MalignancyNetherlands
-
University Hospital RijekaUniversity of RijekaCompleted
-
Juan A. ArnaizCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Johnson & Johnson Pharmaceutical Research & Development...TerminatedVentilator-Associated PneumoniaUnited States, Australia, Germany, France, Spain, Argentina, Mexico, Portugal, India, Romania, Turkey, Ukraine, Canada, Belgium, Brazil, Philippines, Russian Federation, Hungary, Israel, Thailand, Guatemala